Exelixis announces results from phase 2 investigator-sponsored trial of cabozantinib
Exelixis announced results from a phase 2 investigator-sponsored trial of cabozantinib for first-line treatment of metastatic radioiodine-refractory differentiated thyroid carcinoma. The primary endpoint of the trial objective response rate was achieved by 54 percent of patients. February 13, 2018